/
KPTI
$10.09-$0.13 (-1.22%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$231.4M
23M shares
52-week range
$3.65 – $10.99
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.52%
Moderate
Price (6 mo)
Loading chart…
Change$-149.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Cost of revenue | $161.4M | $2.4M | $2.7M | $3.4M | $5.2M | $4.9M | $6.0M | $5.9M |
| Gross profit | −$131.0M | $38.5M | $105.4M | $206.4M | $151.9M | $141.1M | $139.2M | $140.1M |
| Gross margin | -431.9% | 94.1% | 97.5% | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| R&D | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | $125.6M |
| Operating income | −$179.9M | −$189.3M | −$171.8M | −$98.3M | −$142.2M | −$129.5M | −$119.4M | −$90.7M |
| EBITDA | −$175.2M | −$182.9M | −$167.9M | −$97.0M | −$139.3M | −$118.4M | −$38.6M | −$149.9M |
| Net income | −$178.4M | −$199.6M | −$196.3M | −$124.1M | −$165.3M | −$143.1M | −$76.4M | −$196.0M |
| Net margin | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (diluted) | -47.11 | -48.32 | -40.87 | -24.75 | -30.28 | -18.79 | -9.41 | -17.93 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $137M | $-4.08 | $-4.17–$-3.99 | 3 |
| 2027 | $155M | $-3.12 | $-3.52–$-2.78 | 2 |
| 2028 | $230M | $-1.54 | $-3.45–$-0.56 | 3 |
| 2029 | $418M | $1.49 | $1.33–$1.69 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
www.karyopharm.com- Employees
- 228
- IPO / List date
- Nov 6, 2013
- HQ
- NEWTON, MA
Held by traders on TradeandTell
No one on the platform currently holds KPTI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 105,414 | $587.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-02-26 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded KPTI yet.
